"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 5 | 8 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 5 | 2 | 7 |
| 2013 | 3 | 2 | 5 |
| 2014 | 5 | 2 | 7 |
| 2015 | 5 | 3 | 8 |
| 2016 | 14 | 9 | 23 |
| 2017 | 197 | 117 | 314 |
| 2018 | 178 | 88 | 266 |
| 2019 | 66 | 31 | 97 |
| 2020 | 25 | 28 | 53 |
| 2021 | 9 | 21 | 30 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Uncovering antiobesity-related hypertension targets and mechanisms of metformin, an antidiabetic medication. Bioengineered. 2021 12; 12(1):4757-4767.
-
Analysis of continuous glucose tracking data in people with type 1 diabetes after COVID-19 vaccination reveals unexpected link between immune and metabolic response, augmented by adjunctive oral medication. Int J Clin Pract. 2021 Dec; 75(12):e14714.
-
COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study). BMJ Open. 2021 09 02; 11(9):e049782.
-
Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021 Sep; 179:109031.
-
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
-
Rev Med Suisse. 2021 08 25; 17(747):1383-1384.
-
From Fighting Critters to Saving Lives: Polyphenols in Plant Defense and Human Health. Int J Mol Sci. 2021 Aug 20; 22(16).
-
COVID-19 and Diabetes. Annu Rev Med. 2022 01 27; 73:129-147.
-
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9). Diabetes Metab J. 2021 07; 45(4):619-620.
-
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9). Diabetes Metab J. 2021 07; 45(4):615-616.